RxDoctor Payments Data

Jeffrey Wartman, MD

Internal Medicine · Riverview, FLNPI 1295730414

Payments from drug & device makers

$5,770in general payments, 2019–2025

Across 349 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$615
  • Lilly USA, LLC$441
  • Novo Nordisk$434
  • AstraZeneca$427
  • Amgen$349
  • Boehringer Ingelheim$320
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$5,67698%
  • Education$341%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,770 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$174,199
Medicare patients
370
Services billed
3,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$105,659
FarxigaDapagliflozin Propanediol60$82,561
JardianceEmpagliflozin59$79,167
XareltoRivaroxaban49$70,550
JanuviaSitagliptin Phosphate46$67,981
MounjaroTirzepatide43$58,682
OzempicSemaglutide28$34,109
ArexvyRsvpref3 Antigen/As01e/Pf59$18,302
InvokanaCanagliflozin17$14,364
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,756
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$9,194
ShingrixVaricella-Zoster Ge/As01b/Pf43$8,729
Atorvastatin Calcium618$5,266
Levothyroxine Sodium284$3,048
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$3,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$206$105,65993 claims
Johnson & JohnsonXarelto, Invokana$281$84,91466 claims
AstraZenecaFarxiga$427$82,56160 claims
Boehringer IngelheimJardiance$320$79,16759 claims
MerckJanuvia$151$67,98146 claims
Lilly USA, LLCMounjaro$441$58,68243 claims
Novo NordiskOzempic$434$34,10928 claims
GSKArexvy, Shingrix$99$27,031102 claims
AbbVieSynthroid$615$2,50361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →